Table 2.
Prevalence of Antithrombotic Prescription in Paroxysmal versus Persistent Atrial Fibrillation Patients with a Moderate to High Risk of Stroke (CHADS2 Score ≥2)
| Therapy | Paroxysmal Atrial Fibrillation (N=56,513) |
Persistent Atrial Fibrillation (N=15,459) |
p Value |
|---|---|---|---|
| Antithrombotic therapy | <0.001 | ||
| Any oral anticoagulant therapy only | 26.3% | 36.1% | |
| Any oral anticoagulant therapy and any antiplatelet therapy | 24.1% | 28.2% | |
| Any antiplatelet therapy only | 35.1% | 25.0% | |
| No therapy | 14.5% | 10.8% |
Categorical data are reported as percentages.
Oral anticoagulant therapy was defined as prescription of either warfarin, dabigatran, or rivaroxaban. Antiplatelet therapy was defined as prescription of either individual or combination of aspirin, clopidogrel, ticlopidine, prasugrel, and/or dipyridamole.